Ventricular function in cirrhosis and portasystemic shunt: A two‐dimensional echocardiographic study

Helmut Keller, Vera Bezjak, Beatrice Stegaru, Jan Buss, Eggert Holm, Dieter L. Heene – 1 May 1988 – Cardiovascular alterations such as increased heart rate, high cardiac output, reduced systemic vascular resistance, and in most of the cases, increased contractility parameters have been recognized in patients with advanced liver disease.

Amiodarone‐induced hepatic phospholipidosis: Correlation of morphological and biochemical findings in an animal model

Mauro Pirovino, Otfried Müller, Thomas Zysset, Ueli Honegger – 1 May 1988 – Morphological and biochemical investigations were performed in guinea pigs after 1, 3, 5 and 16 weeks of amiodarone feeding. The most prominent morphological finding was an increase in dense bodies in hepatocytes, Kupffer cells and in bile duct epithelia, reaching a maximum after 5 weeks of treatment according to morphometric analysis. Similar time courses were observed for the serum and liver tissue concentrations of amiodarone and desethylamiodarone and the—albeit minimal—extent of hepatocellular necrosis.

Early midzonal cell death during low‐flow hypoxia in the isolated, perfused rat liver: Protection by allopurinol

Mark E. Marotto, Ronald G. Thurman, John J. Lemasters – 1 May 1988 – Trypan blue uptake and lactate dehydrogenase release were measured as indices of irreversible cell damage in isolated, perfused rat livers during low‐flow hypoxia. In livers from fasted rats perfused in the anterograde direction, trypan blue uptake took place beginning at about 45 min of hypoxia. Cells which took up trypan blue first were located in narrow bands at the border between anoxic pericentral areas and normoxic periportal regions of the liver lobule.

Hepatocellular carcinoma in type I glycogen storage disease

Joachim Limmer, Wolfgang E. Fleig, Dorothea Leupold, Reinhard Bittner, Hans Ditschuneit, Hans‐Günter Berger – 1 May 1988 – Patients suffering from Type I glycogen storage disease frequently develop hepatic tumors. Some of these were classified as carcinoma, with the majority of tumors representing benign adenomata. However, no evidence exists of malignant transformation of adenomata in these patients.

Detection of hepatitis B virus dna in hepatocellular carcinoma: Analysis by hybridization with subgenomic dna fragments

Jen‐Yang Chen, Tim J. Harrison, Chue‐Shue Lee, Ding‐Shinn Chen, Arie J. Zuckerman – 1 May 1988 – We have previously reported an analysis of DNA extracted from 31 primary liver tumors where, in 25 cases, we found chromosomal integration of hepatitis B virus DNA sequences. We describe here an investigation of the extent of the viral genome at each integration site in 15 of the hepatitis B virus DNA‐positive tumors using subgenomic fragments of the viral genome as probes.

Is anti‐hbc IgM a useful clinical test in patients with HBsAg‐positive chronic hepatitis or primary hepatocellular carcinoma?

Min Chan Lai, Myron J. Tong, Marek J. Nowicki, Shou‐Dong Lee – 1 May 1988 – Seventy HBsAg‐positive patients, including 24 with primary hepatocellular carcinoma, 34 with chronic active hepatitis, 12 with chronic persistent hepatitis and 30 asymptomatic healthy hepatitis B virus carriers were tested for anti‐HBc IgM using the Corzyme‐M test. Anti‐HBc IgM was detected in 50% of the primary hepatocellular carcinoma patients, 26.5% of the chronic active hepatitis patients, 25% of the chronic persistent hepatitis patients, but in none of the healthy hepatitis B virus carriers.

Absence of seroconversion following treatment with hepatitis B immune globulin containing antibody to human immunodeficiency virus

Michael Phillips, Laurence M. Cummins – 1 May 1988 – Recent studies have demonstrated that commercial preparations of hepatitis B immune globulin often contain antibody to the human immunodeficiency virus. The presence of this antibody has aroused concerns that treatment with hepatitis B immune globulin might passively induce human immunodeficiency virus antibody seropositivity, leading to incorrect diagnoses of human immunodeficiency virus exposure.

Clinical value of the guanase screening test in donor blood for prevention of posttransfusional non‐A, non‐B hepatitis

Susumu Ito, Yasuhiro Tsuji, Naoyuki Kitagawa, Ishihara Akihiko, Jyoji Syundo, Yoshiyuki Tamura, Seiichiro Kishi, Hiroyoshi Mori – 1 March 1988 – We adopted an automated method for measuring guanase in donor blood and examined the incidence of posttransfusional non‐A, non‐B hepatitis when donor blood with high guanase activities was excluded. Sixty‐seven (2.4%) of 2,826 units were excluded from use in transfusion because they had guanase activities above 1.71 units per liter. Of 112 recipients, 8 (7%) developed posttransfusional non‐A, non‐B hepatitis.

Pathology of chronic hepatitis b virus infection in children: With special reference to the intrahepatic expression of hepatitis B virus antigens

Hey‐Chi Hsu, Yon‐Ho Lin, Mei‐Hwei Chang, Ih‐Jen Su, Ding‐Shinn Chen – 1 March 1988 – The clinical, virologic and pathologic features of chronic hepatitis B virus infection were studied in 66 children, of whom 29 were symptomatic and 37 asymptomatic. The majority (79%) of symptomatic children had histologically aggressive diseases: 11 had chronic active hepatitis and 10 had cirrhosis. In contrast, most asymptomatic children had nonaggressive diseases (35 cases); only 2 had chronic active hepatitis.

Subscribe to